Do you have stage 1, HER2-positive breast cancer? Has your surgery already been completed? If so, you may be able to take part in a study to help us learn more about a combination of medications to treat your cancer.

Have you been diagnosed with high-risk early triple-negative breast cancer (TNBC) without mutations in the BRCA1 or BRCA2 gene? If you still have evidence of TNBC in your breast or lymph node tissue after receiving treatment and surgery, you may qualify for this clinical research study. This study will test an experimental drug combination to find out which treatment is better at delaying the return of cancer.

This is a Phase III study to help us improve outcomes of patients with ER+/HER2- early breast cancer with intermediate or high risk for disease recurrence. This study is for patients who have completed definitive locoregional therapy and standard adjuvant endocrine therapy for at least 2 years and up to 5 years without disease recurrence. In this study, we want to learn if a new oral "SERD" therapy called Camizestrant is helpful in reducing chance of recurrence. Talk to your Medical Oncologist for more information about this trial.